Here are the 10-K annual reports from Climb Bio, Inc. (CLYM) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-K covers the audited annual report, with the full financial statements, so if you follow CLYM and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CLYM filings page.
Climb Bio, Inc. is a clinical-stage biotechnology company focused on immune-mediated diseases. Its lead antibody, budoprutug, targets CD19 to deplete pathogenic B cells in primary membranous nephropathy (pMN), immune thrombocytopenia (ITP) and systemic lupus erythematosus (SLE). Budoprutug has orphan-drug designation for pMN, encouraging Phase 1b data in pMN, and multiple ongoing Phase 1/2 trials in pMN, ITP and SLE, including an intravenous and a high‑concentration subcutaneous formulation.
The company’s second program, CLYM116, is a next-generation anti‑APRIL ‘sweeper’ antibody aimed at IgA nephropathy and other B‑cell–mediated diseases. Early preclinical work suggests deep and durable APRIL and IgA suppression, and Phase 1 trials in healthy volunteers and parallel studies with partner Mabworks in China are underway. Climb Bio estimates its targeted indications encompass more than 500,000 U.S. patients, with broader potential across roughly 2 million people living with immune‑mediated diseases.